Please login to the form below

Not currently logged in
Email:
Password:

Precision medicine

This page shows the latest Precision medicine news and features for those working in and with pharma, biotech and healthcare.

Novartis bolsters radioligand therapy pipeline with new licence agreement

Novartis bolsters radioligand therapy pipeline with new licence agreement

Radioligand therapies are a new potential class of precision oncology drugs. ... Radioligand therapies have emerged as a new potential class of precision oncology drugs.

Latest news

  • Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

    177Lu-PSMA-617 is a type of precision medicine that combines a targeting compound – ligand – and a therapeutic radioisotope. ... This groundbreaking data confirms our belief in the potential of 177Lu-PSMA-617 to reimagine outcomes for these patients

  • Servier to acquire Agios’ oncology business in $1.8bn deal Servier to acquire Agios’ oncology business in $1.8bn deal

    area. “The strategic acquisition of Agios’ oncology business, including its precision medicine portfolio and pipeline, is aligned with our ambition to become a recognised player in oncology and further supports our

  • AstraZeneca to acquire Alexion for $39bn AstraZeneca to acquire Alexion for $39bn

    programmes. AZ hopes to combine its own precision medicine expertise with Alexion’s specialist rare disease knowledge to leverage its capabilities in a number of therapy areas, including haematology, nephrology, neurology, ... We look forward to

  • 20/20 vision 20/20 vision

    Pharmaceutical communicators will also need to adapt their skills and approaches with the increasing demands of drug development, combined with the personalisation of therapies for rare diseases, as well as precision ... medicine responding to genomic

  • FDA clears Blueprint’s $32k-per-month GI cancer drug FDA clears Blueprint’s $32k-per-month GI cancer drug

    The approval “ushers in a new era of precision medicine in this disease,” according to NAVIGATOR investigator Michael Heinrich of Oregon Health &Science University in the US. ... benefits of this promising new medicine”.

More from news
Approximately 3 fully matching, plus 40 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 6 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 20 fully matching, plus 18 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics